Menu
November 28, 2023 : Median Technologies, a leading provider of imaging phenotyping solutions for clinical trials, announced today the rebranding of its flagship product, iBiopsy®, to eyonis™. This rebranding marks a significant milestone in the company’s evolution and reflects its commitment to providing advanced imaging solutions that empower precision medicine.
“The rebranding of iBiopsy® to eyonis™ represents a pivotal moment in our journey,” stated Fredrik Bragde, CEO of Median Technologies. “eyonis™ embodies our vision for the future of clinical imaging, where artificial intelligence and advanced algorithms are seamlessly integrated into the clinical workflow to accelerate drug development and bring life-changing therapies to patients faster.”
eyonis™ is a comprehensive imaging phenotyping platform that utilizes artificial intelligence (AI) and machine learning to extract quantitative information from medical images, providing researchers with a deeper understanding of disease progression and treatment response. The platform supports various imaging modalities, including MRI, CT, PET, and ultrasound, offering a versatile solution for clinical trials across diverse therapeutic areas.
“eyonis™ is more than just a rebranded product; it represents a leap forward in clinical imaging,” remarked Dr. Philippe Thariat, Chief Medical Officer at Median Technologies. “By harnessing the power of AI, eyonis™ enables researchers to extract meaningful insights from medical images, leading to more informed clinical decisions and improved patient outcomes.”
The rebranding to eyonis™ coincides with the launch of several enhancements to the platform, including:
These enhancements further strengthen eyonis™’s position as a leading imaging phenotyping platform, providing researchers with the tools they need to accelerate drug development and bring life-changing therapies to patients faster.
Median Technologies’ rebranding of iBiopsy® to eyonis™ marks a significant step forward in the company’s efforts to revolutionize clinical imaging. The new name reflects the platform’s evolved capabilities and role in driving precision medicine initiatives.
eyonis™’s ability to leverage AI and machine learning to extract meaningful insights from medical images is a game-changer for clinical trials. By providing researchers with a deeper understanding of disease progression and treatment response, eyonis™ has the potential to accelerate drug development and improve patient outcomes.
The platform’s enhanced capabilities and streamlined integration with EDC systems further enhance its value proposition. It is an indispensable tool for clinical researchers seeking to optimize trial design and accelerate the delivery of effective therapies to patients.
The rebranding of iBiopsy® to eyonis™ signals a new era of clinical imaging. AI and advanced algorithms empower researchers to make more informed decisions, optimize clinical trials, and ultimately bring life-changing therapies to patients faster.
